Hypercholesterolaemia treated with inclisiran.
Ugeskr Laeger
; 186(24)2024 Jun 10.
Article
en Da
| MEDLINE
| ID: mdl-38903035
ABSTRACT
In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Inhibidores de PCSK9
/
Hiperlipoproteinemia Tipo II
Idioma:
Da
Revista:
Ugeskr Laeger
Año:
2024
Tipo del documento:
Article